Will platinib successfully enter medical insurance in 2025?

As of2025, the original drug of Pralsetinib (Pralsetinib) has been launched in the Chinese market, but it has not yet been successfully included in the medical insurance system. This means that although platinib has been approved to enter the market and is available for patients to purchase, patients need to bear the cost of the drug themselves and cannot receive price support through medical insurance reimbursement. In China, the price of platinib is relatively expensive. The common packaging specifications are 100mg 60 tablets and 100mg 120 tablets. The price is about more than 20,000 yuan, and in some areas it may even reach 60,000 yuan. This price is a heavy burden for most patients, especially the larger doses required for long-term treatment.

Platinib is a targeted drug used to treat ALK mutation-positive non-small cell lung cancer (NSCLC). Its clinical efficacy is relatively significant, but the high cost of the drug puts some patients under greater financial pressure during actual use. Since it has not yet been included in the medical insurance system, patients do not have the support of medical insurance reimbursement when purchasing drugs, and may need to pay for the drugs out of pocket or seek other financial assistance channels. Compared with other drugs that have been included in medical insurance, the price of platinib is still in the category of high-end drugs in China.

Compared with the domestic market, the overseas price of platinib is more expensive, especially in countries such as the United States, where the price of platinib usually fluctuates between 40,000 to more than 100,000 yuan. Even in some developed countries, drug costs faced by patients are still high. Although the cost of drugs is relatively high, their clinical and therapeutic effects are still highly praised by doctors and patients. Therefore, platinib, as an innovative drug, although expensive, still provides a new treatment option for many patients, especially for patients with ALK mutation-positive non-small cell lung cancer.

In view of the high drug costs, generic drugs of platinib have been released in overseas markets. The generic version of Platinib produced in Laos has a specification of 100mg*120 tablets. The price is only more than 3,000 yuan, and its ingredients are almost identical to the original drug. Although generic drugs are less expensive, patients and doctors need to weigh their choices carefully due to differences in quality control and production standards. Nonetheless, the emergence of generic drugs has provided more affordable treatment options for some financially disadvantaged patients, especially if they are not covered by health insurance.

Reference materials:https://gavreto.com/